1 of 1
Story summary
- The U.S. Food and Drug Administration approved Merck's regimen Idvynso, combining doravirine and islatravir, for certain adults.
- The approval could replace some antiretroviral therapies for HIV-1 in adults.
- In late-stage studies, Merck's regimen matched Gilead's Biktarvy in effectiveness.
- RBC Capital Markets analyst Trung Huynh cautions that initial commercial impact may be limited, with growth dependent on approvals for untreated patients.
- Globally, about 40.8 million people live with HIV.
